Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer
Recruiting now · Phase 4
Conditions studied: Cervical Cancer
In brief
This is a nationwide, multicenter, registry-based prospective cohort study to assess real-world effectiveness of treatment with a pembrolizumab containing regimen in persistent, recurrent, or metastatic cervical cancer. Patients in the observation cohort continue treatment according to standard of care. In the discontinuation cohort, patients discontinue their maintenance treatment with pembrolizumab (with or without discontinuation of bevacizumab). Patients may choose to discontinue pembrolizumab prematurely (with or without discontinuation of bevacizumab) if they achieve a confirmed CR or a confirmed PR to treatment, or on patient's request or due to toxicity. If an eligible patient chooses not to discontinue treatment early they will remain in the observation cohort. The duration of the trial for the individual patient will be until two years from the start of treatment. Survival follow-up will continue for a maximum of 10 years
Key facts
- Study ID
- NCT07645625
- Run by
- University Medical Center Groningen
- People needed
- 261
- Starts
- 2026-05-11
- Expected to finish
- 2039-02-01
- Last updated by the study team
- 2026-06-29
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- LUMC — Leiden, Netherlands (enrolling)
- Catharina Ziekenhuis — Eindhoven, Netherlands (enrolling)
- University Mecdical Center Groningen — Groningen, Netherlands (enrolling)
- Maastricht UMC — Maastricht, Netherlands
- Radboud UMC — Nijmegen, Netherlands
- Erasmus MC — Rotterdam, Netherlands
- UMC Utrecht — Utrecht, Netherlands
- Amsterdam UMC — Amsterdam, Netherlands
- Isala Klinieken — Zwolle, Netherlands
- Antoni van Leeuwenhoek Ziekenhuis — Amsterdam, Netherlands
- Medisch Spectrum Twente — Enschede, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.